Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDX-585 in advanced malignancies
NCT05788484Phase 1Completed
- Sponsor
- Celldex Therapeutics
- Start
- May 2023
- Primary completion
- May 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CDX-585 in solid tumor, non-small cell lung cancer (NSCLC), gastric cancer (GC) and 11 more, sponsored by Celldex Therapeutics. Primary endpoints: Maximum Tolerated Dose at 12 months and Safety Evaluation by Tumor Type at 6 months. Started May 2023; status: completed.
02
Drugs
CDX-585
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)gastric cancer (GC)head and neck cancer (HNC)ovarian cancer
Beyond the preview
Go deeper on NCT05788484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05788484.